Previous close | 2.2170 |
Open | 2.1910 |
Bid | 2.1810 x 600000 |
Ask | 2.2240 x 600000 |
Day's range | 2.1910 - 2.2170 |
52-week range | 2.1470 - 2.7750 |
Volume | |
Avg. volume | 320 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Cerecin Inc., a clinical-stage biotechnology company at the forefront of developing innovative neurotherapeutics, is pleased to announce the establishment of a Memorandum of Understanding (MOU) with A*STAR's Institute of Molecular and Cell Biology (IMCB). This collaboration aims to accelerate research and treatment initiatives for neurological disorders and diseases to enhance overall health and brain function.